Factor XII truncation accelerates activation in solution.

de Maat, S; Clark, C C; Boertien, M; Parr, N; Sanrattana, W; Hofman, Z L M; Maas, C

de Maat, S; Clark, C C; Boertien, M; Parr, N; Sanrattana, W; Hofman, Z L M; Maas, C.

Affiliation

de Maat S; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Clark CC; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Boertien M; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Parr N; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Sanrattana W; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Hofman ZLM; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Maas C; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

J Thromb Haemost ; 17(1): 183-194, 2019 01.

Article de En | MEDLINE | ID: mdl-30394658

Sujet(s)
Mots clés

bradykinin; factor XII; hereditary angioedema; neutrophil elastase; plasma kallikrein

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Coagulation sanguine / Facteur XII / Facteur XIIa / Kallicréine plasmatique Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: J Thromb Haemost Sujet du journal: HEMATOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Pays-Bas Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google